[CAS NO. 1943733-16-1] YU238259
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1943733-16-1]
Store
Catalog
SLK-S8379
Brand
Selleck
CAS
1943733-16-1
DESCRIPTION [1943733-16-1]
Overview
| MDL | MFCD30532769 |
|---|---|
| Molecular Weight | 459.95 |
| Molecular Formula | C22H22ClN3O4S |
| SMILES | O=C(NCCC1=NC=C(Cl)C=C1)C2=CC=C(CNS(=O)(C3=CC=C(OC)C=C3)=O)C=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1741 mL | 10.8707 mL | 21.7415 mL |
| 5 mM | 0.4348 mL | 2.1741 mL | 4.3483 mL |
| 10 mM | 0.2174 mL | 1.0871 mL | 2.1741 mL |
| 50 mM | 0.0435 mL | 0.2174 mL | 0.4348 mL |
Description
YU238259 is a novel inhibitor of , but does not inhibit non-homologous end-joining (NHEJ), in cell-based GFP reporter assays.
Targets
| HDR [1] |
In vitro
YU238259 exhibits potent synthetic lethality in the setting of DNA damage response and DNA repair defects. Treatment with YU238259 is not only synergistic with ionizing radiation (IR), etoposide, and PARP inhibition, but this synergism is heightened by BRCA2-deficiency. Synthetic lethality of YU238259 in HDR-deficient cells results from accumulation of unresolved DSBs following additional inhibition of residual HDR pathway activity. Inhibition of HDR activity by YU238259 has little to no effect on the NHEJ pathway. YU238259 sensitizes tumor cells to radiation therapy and DSB-inducing chemotherapy .
In vivo
Growth of BRCA2-deficient human tumor xenografts in nude mice is significantly delayed by YU238259 treatment even in the absence of concomitant DNA-damaging therapy.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.